Heritage Investors Management Corp Has $40.68 Million Stake in Merck & Co., Inc. $MRK

Heritage Investors Management Corp lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 4.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 316,592 shares of the company’s stock after selling 15,875 shares during the period. Merck & Co., Inc. accounts for about 1.1% of Heritage Investors Management Corp’s portfolio, making the stock its 24th largest position. Heritage Investors Management Corp’s holdings in Merck & Co., Inc. were worth $40,682,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of MRK. Somerset Trust Co grew its stake in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after buying an additional 81 shares during the period. Stonebridge Financial Group LLC raised its stake in Merck & Co., Inc. by 0.9% during the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock worth $1,124,000 after buying an additional 81 shares during the period. Stronghold Wealth Management L.L.C. raised its stake in Merck & Co., Inc. by 2.6% during the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock worth $416,000 after buying an additional 82 shares during the period. Lederer & Associates Investment Counsel CA boosted its holdings in Merck & Co., Inc. by 0.9% in the second quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company’s stock worth $1,234,000 after acquiring an additional 84 shares in the last quarter. Finally, Pine Haven Investment Counsel Inc grew its stake in Merck & Co., Inc. by 0.6% in the second quarter. Pine Haven Investment Counsel Inc now owns 14,273 shares of the company’s stock valued at $1,834,000 after acquiring an additional 86 shares during the period. 76.07% of the stock is owned by institutional investors.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Insider Transactions at Merck & Co., Inc.

In related news, EVP David R. Maraldo sold 18,706 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president directly owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard R. Deluca sold 11,699 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the completion of the transaction, the executive vice president directly owned 110,167 shares of the company’s stock, valued at $14,501,282.21. The trade was a 9.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on MRK shares. BMO Capital Markets boosted their price objective on Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday. Citigroup started coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price on the stock. JPMorgan Chase & Co. lifted their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. UBS Group boosted their price target on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Morgan Stanley upgraded shares of Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $116.00 to $179.00 in a report on Thursday. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $144.10.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $152.43 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The company has a market capitalization of $376.07 billion, a price-to-earnings ratio of 121.94, a PEG ratio of 6.43 and a beta of 0.19. The stock has a 50 day moving average of $128.09 and a 200 day moving average of $121.23. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $154.49.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.